Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum
British Journal of Dermatology2015Vol. 174(4), pp. 839–846
Citations Over TimeTop 1% of 2015 papers
Abstract
The majority of patients improved with ustekinumab. Although no biomarker was discovered, low LTA4H concentrations with mild disease severity may be predictive of the effectiveness of ustekinumab.
Related Papers
- → Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience(2020)17 cited
- → Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab(2009)21 cited
- → Hidradenitis suppurativa in Crohn’s disease during adalimumab therapy: a paradox?(2016)16 cited
- Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.(2014)
- → Hidradenitis suppurativa successfully treated with adalimumab(2015)